CLINICAL TRIALS PROFILE FOR DEFEROXAMINE MESYLATE

All Clinical Trials for Deferoxamine Mesylate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00598572 ↗	Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage	Completed	Hartford Hospital	Phase 1	2008-07-01	Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗	Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage	Completed	Massachusetts General Hospital	Phase 1	2008-07-01	Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗	Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage	Completed	Medical College of Wisconsin	Phase 1	2008-07-01	Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗	Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage	Completed	Medical University of South Carolina	Phase 1	2008-07-01	Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
NCT00598572 ↗	Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 1	2008-07-01	Animal studies show that the breakdown of blood results in iron accumulation in the brain after brain hemorrhage (ICH); and that iron plays a role in brain injury in ICH patients. Deferoxamine (DFO) has been extensively used in clinical practice for more than 30 years to remove excessive iron from the body, and has been shown to provide some benefit in animal studies of ICH. Therefore, we plan to undertake this study to evaluate the safety and tolerability of treatment with DFO in patients with ICH, and to determine the maximal tolerated dose to be used in future studies to determine if treatment with DFO can improve the outcome of patients with ICH. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent studies to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with DFO will improve patients' outcome. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.

Clinical Trial Conditions for Deferoxamine Mesylate

Condition Name

Condition Name for Deferoxamine Mesylate
Intervention	Trials
Intracerebral Hemorrhage	5
Myelodysplastic Syndrome	1
Spontaneous Intracerebral Hemorrhage	1
Supratentorial Intracerebral Haemorrhage	1

Condition MeSH

Condition MeSH for Deferoxamine Mesylate
Intervention	Trials
Hemorrhage	5
Cerebral Hemorrhage	5
Leukemia	1
Syndrome	1

Clinical Trial Locations for Deferoxamine Mesylate

Trials by Country

Trials by Country for Deferoxamine Mesylate
Location	Trials
United States	37
Canada	7
China	3
Australia	1

Trials by US State

Trials by US State for Deferoxamine Mesylate
Location	Trials
Massachusetts	4
Michigan	3
Texas	2
South Carolina	2
Rhode Island	2

Clinical Trial Progress for Deferoxamine Mesylate

Clinical Trial Phase

Clinical Trial Phase for Deferoxamine Mesylate
Clinical Trial Phase	Trials
PHASE3	1
Phase 2	3
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for Deferoxamine Mesylate
Clinical Trial Phase	Trials
Terminated	2
Completed	2
Recruiting	2

Clinical Trial Sponsors for Deferoxamine Mesylate

Sponsor Name

Sponsor Name for Deferoxamine Mesylate
Sponsor	Trials
Beth Israel Deaconess Medical Center	3
Hartford Hospital	3
University of Calgary	3

Sponsor Type

Sponsor Type for Deferoxamine Mesylate
Sponsor	Trials
Other	95
NIH	3

DEFEROXAMINE MESYLATE: Clinical Trials Update and Market Outlook

Last updated: April 27, 2026

What is deferoxamine mesylate and why does it matter commercially?

Deferoxamine mesylate (deferoxamine) is an injectable iron chelator used to reduce excess iron in settings that include iron overload from transfusion-dependent conditions. The commercial profile is shaped by (1) the addressable population that can use chelation therapy, (2) route-of-administration preferences, (3) safety tolerability versus oral competitors, and (4) pricing and reimbursement in hematology and related care pathways.

What is the current clinical-trials status landscape?

No complete, decision-grade clinical-trials update (latest enrollment status, phase, sites, primary endpoints, and readouts) can be produced from the information available in this chat.

What is the competitive market structure for iron chelation?

The iron chelation market is dominated by established brands with differentiated administration routes and tolerability profiles. Deferoxamine is typically positioned around older-generation parenteral chelation, with newer entrants shifting patient preference toward oral regimens where clinically appropriate. Commercial traction for any chelator depends on:

• Treatment setting (transfusion-dependent vs other iron-overload etiologies)
• Patient selection criteria and guideline adoption
• Parenteral vs oral logistics
• Adverse event management (with particular focus on ocular and auditory toxicities historically associated with chelation class)

How is the market segmented for deferoxamine use?

Commercial adoption usually correlates with segmentation by iron-overload cause and care pathway:

• Transfusion-dependent populations where chelation is standard of care
• Patients for whom oral therapy is not suitable (tolerability, interactions, adherence barriers, or clinician preference)
• Health systems that continue to support parenteral chelation in specific reimbursement frameworks

What is the forecast logic for deferoxamine mesylate?

A credible market projection for deferoxamine depends on trends in:

• Transfusion epidemiology (demand growth for chelation broadly)
• Switch-to-oral behavior (competitive pressure on parenteral products)
• Uptake in guideline-based centers
• Supply and manufacturing continuity for injectables
• Pricing pressure and payer formularies
• Evidence generation (new clinical data can expand or protect niches)

No quantified forecast can be stated from the information available in this chat without producing unverifiable figures.

What clinical endpoints drive adoption in iron chelation?

For chelators, clinical value and payer coverage generally track:

• Biomarker reduction of iron burden (for example, ferritin and liver iron measures)
• Avoidance or delay of organ complications from iron overload
• Safety and monitoring parameters
• Adherence and real-world administration feasibility

What are the practical commercial risks for deferoxamine?

Key risks for an injectable chelator include:

• Competitive displacement by oral chelators where eligible
• Treatment burden (infusion logistics and monitoring)
• Safety perceptions impacting clinician and patient willingness
• Formularies limiting coverage if cheaper or easier oral alternatives exist

What are the practical commercial tailwinds for deferoxamine?

Tailwinds usually come from:

• Continued use in patient subgroups not aligned with oral therapy
• Clinical familiarity and established monitoring protocols in hematology centers
• Long-term relationships within hospital procurement channels for injectables

What should investors and R&D leaders focus on for this asset?

For deferoxamine mesylate, decision-grade diligence typically centers on:

• Evidence of clinical differentiation in current practice (not just historical efficacy)
• Current trial pipeline status and any new label-expansion studies
• Commercial access constraints (hospital tenders, payer reimbursement, and availability)
• Manufacturing and regulatory continuity for injectables

Key Takeaways

• Deferoxamine mesylate is a parenteral iron chelator whose commercial performance depends on injectable adoption within iron-overload care pathways.
• A complete clinical-trials update with phase, enrollment, and readouts cannot be generated from the information in this chat.
• Market projection requires quantified inputs (current sales, eligible population estimates, competitive shares, reimbursement rules) that are not provided here.

FAQs

1. Is deferoxamine mesylate currently in active late-stage clinical development?
   The necessary, current-stage trial facts are not available in this chat.

2. Does deferoxamine compete mainly with oral iron chelators?
   Yes, it competes where oral options are eligible, but the exact competitive set and share-by-setting are not provided here.

3. What endpoints matter most for adoption of iron chelators?
   Uptake typically tracks iron-burden reduction, organ-risk mitigation, safety, and monitoring feasibility.

4. Why can an injectable chelator retain a niche despite oral competition?
   It can be used in patient subgroups where oral therapy is unsuitable or when care pathways favor parenteral regimens.

5. Can a market forecast be computed from this request alone?
   Not to a decision-grade standard; quantified inputs for sizing, pricing, and share are not present.

References

[1] No sources were provided in the request, and no external citations were supplied.